通窍鼻炎胶囊联合孟鲁司特钠治疗变应性鼻炎的临床研究

目的探讨通窍鼻炎胶囊联合孟鲁司特钠片治疗变应性鼻炎的临床疗效。方法选取2019年6月—2021年4月天津市第四中心医院收治的120例变应性鼻炎患者作为研究对象,全部患者按照随机数字表法分为对照组和治疗组,每组各60例。对照组患者口服孟鲁司特钠片,10 mg/次,1次/d。治疗组患者在对照组治疗的基础上口服通窍鼻炎胶囊,2.0 g/次,3次/d。两组患者连续治疗4周。观察两组的临床疗效,比较两组患者的临床症状体征评分、鼻腔容积、最小截面积、鼻阻力。检查两组治疗前后血清嗜酸性细胞阳离子蛋白(ECP)、白细胞介素-33(IL-33)、特异性IgE(sIgE)水平。结果治疗后,治疗组患者的总有效率为95.00%,对照组患者总有效率为83.33%,两组有明显差异(P0.05)。治疗后,两组鼻痒评分、鼻塞评分、流涕评分、喷嚏评分、体征评分显著降低(P0.05),且治疗组鼻痒评分、鼻塞评分、流涕评分、喷嚏评分、体征评分降低更明显(P0.05)。治疗后,两组的最小截面积、鼻阻力明显减少,鼻腔容积明显升高(P0.05);治疗后,治疗组的最小截面积、鼻阻力低于对照组,鼻腔容积高于对照组(P0.05)。治疗后,两组的血清ECP、IL-33、sIgE水平显著降低(P0.05),治疗组血清ECP、IL-33、sIgE水平较对照组降低更明显(P0.05)。结论通窍鼻炎胶囊联合孟鲁司特钠片治疗变应性鼻炎具有较好的临床疗效,可有效改善患者的鼻腔症状和临床症状体征,减轻炎症反应。

Clinical study on Tongqiao Biyan Capsules combined with montelukast sodium in treatment of allergic rhinitis

Objective To investigate the clinical efficacy of Tongqiao Biyan Capsules combined with Montelukast Sodium Tablets in treatment of allergic rhinitis. Methods Patients (120 cases) with allergic rhinitis in Tianjin Fourth Central Hospital from June 2019 to April 2021 were divided into control and treatment groups according to the random number table method, and each group had 60 cases. Patients in the control group were po administered with Montelukast Sodium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Tongqiao Biyan Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the clinical symptoms score, signs score, nasal volume, minimum cross-sectional area, and nasal resistance in two groups were compared. The serum levels of ECP, IL-33, and sIgE were measured before and after treatment in two groups. Results After treatment, the total effective rate was 95.00% in the treatment group, and 83.33% in the control group, and there was significant difference between two groups (P<0.05). After treatment, the scores of nasal itching, runny nose, sneezing, nasal obstruction, and signs, and signs scores in two groups were significantly decreased (P<0.05), and the symptoms scores and signs scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the nasal resistance and minimum cross-sectional area in two groups were significantly decreased, but the nasal cavity volume in two groups were significantly increased (P<0.05). After treatment, the nasal resistance and minimum cross-sectional area of the treatment group were lower than those of the control group, but the nasal cavity volume of the treatment group was higher than that of the control group (P<0.05). After treatment, the serum levels of ECP, IL-33, and sIgE in two groups were significantly lower (P<0.05), and the serum levels of ECP, IL-33, and sIgE in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Tongqiao Biyan Capsules combined with Montelukast Sodium Tablets has clinical curative effect in treatment of allergic rhinitis, can effectively improve nasal symptoms, clinical symptoms and signs, and reduce inflammatory reaction.